SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC
Ardent Health, Inc.
ARDT
Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S and operating in eight growing mid-sized urban markets across six states Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas. The main focus on people and investments in services and technologies.
Last trade$17.84
Day change-$0.26 (-1.44%)
Day range$17.78 – $18.34
Volume227,366
Market cap$2.55B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.55B
Price / earnings
17.45×
Price / book
1.83×
Price / sales
0.4×
EV / sales
0.45×
EV / EBITDA
5.66×
Profitability
Earnings per share
$1.04
Return on assets
2.73%
Return on equity
10.47%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.79×
Current ratio
2.26×
Quick ratio
2.14×
Cash ratio
0.8×
Cash flow
Price / cash flow
5.29×
Price / free cash flow
9.04×
Free cash flow
$282.3M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ARDT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.62B
$1.62B
$1.6B
$1.61B
$1.58B
$1.65B
$1.5B
$1.61B
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.62B
$1.62B
$1.6B
$1.61B
$1.58B
$1.65B
$1.5B
$1.61B
Selling, general and administrative
$975.75M
$1B
$978.5M
$961.08M
$982.05M
$968.71M
$938.51M
$940.27M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$1.53B
$1.57B
$1.52B
$1.5B
$1.56B
$1.51B
$1.41B
$1.45B
Operating income
$95.34M
$55.77M
$86.8M
$104.75M
$16.46M
$136.72M
$88.37M
$157.57M
Interest expense
-$15.32M
-$12.57M
-$12.21M
-$12.38M
-$13.91M
-$14.73M
-$14.18M
-$13.53M
Income before taxes
$81.03M
$43.2M
$74.59M
$92.37M
-$2.2M
$121.99M
$74.2M
$167.25M
Income taxes
$17.64M
$8.51M
$16.1M
$18.11M
-$3.41M
$26.29M
$15.23M
$26.36M
Net income
$63.39M
$34.69M
$58.49M
$74.26M
$1.21M
$95.7M
$58.97M
$140.89M
Net income attributable to common shareholders
$44.52M
$16.9M
$39.85M
$44.96M
-$23.48M
$72.95M
$41.38M
$114.2M
EBITDA
$136.4M
$97.11M
$129.79M
$145.79M
$55.61M
$176.03M
$124.58M
$195.43M
Basic earnings per share
$0.32
$0.12
$0.28
$0.32
-$0.17
$0.52
$0.30
$0.81
Diluted earnings per share
$0.31
$0.12
$0.28
$0.32
-$0.17
$0.52
$0.29
$0.81
Recent news
Company coverage with links to the original publishers.
Ardent Health, Inc. (ARDT) reported Q3 2026 earnings of $0.31 per share, beating consensus estimates of $0.24, with revenues of $1.62 billion slightly exceeding expectations. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revision trends. The stock has outperformed the S&P 500 by 22% year-to-date, but future performance will depend on management guidance and earnings estimate revisions.
Ardent Health, Inc. (ARDT) is drawing attention from options traders due to high implied volatility in its January 15, 2026 $2.50 call options, suggesting market expectations for significant price movement. The company holds a Zacks Rank #3 (Hold) rating in the Medical Services Industry, with analysts slightly raising estimates for the current quarter from 23 to 24 cents per share over the last 30 days.
Ardent Health director Robert DeMichiei purchased 11,260 shares on June 5, 2026, for approximately $98,000 at $8.73 per share, increasing his holdings by 46%. This marks the first open-market insider buy in a year for the hospital operator, with the CFO also purchasing shares the same day. The purchases signal insider confidence despite the stock's 27.51% decline over the past year.
A class action lawsuit has been filed against Ardent Health, Inc. for allegedly reporting inflated accounts receivable and delaying loss recognition on uncollectable accounts during the class period of July 18, 2024 to November 12, 2025. The company revealed a $43 million revenue decrease in Q3 2025 after transitioning to a new accounting system, causing the stock to plummet 34% from $14.05 to $9.30 per share. Investors have until March 9, 2026 to apply as lead plaintiff.
A class action lawsuit has been filed against Ardent Health, Inc. alleging that the company made materially false and misleading statements regarding its Q3 2025 revenue and 2025 EBITDA guidance. The complaint claims revenue was overstated due to inadequate accounts receivable assessments following a new accounting system implementation, and EBITDA guidance was overstated by approximately $57.5 million (9.6%) due to industry-wide cost pressures and payer denials. Investors who purchased Ardent securities between July 18, 2024 and November 12, 2025 are encouraged to join the lawsuit.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.